Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
bovnews1h
Bristol-Myers Squibb Co (BMY) Stock: Greater Than Its Current Valuation?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
thecardiologyadvisor.com2h
AHA Initiative Launched to Reduce Gaps in Care for Hypertrophic Cardiomyopathy
An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.
Cambridge Cognition product used in schizophrenia treatment trial
Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight
Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...
Study identifies risk potential for thousands of mutations of a cancer gene
Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...
manilatimes4h
Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease
Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...
FierceBiotech5h
LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push
Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...
BioSpace10h
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...
Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY)
In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo (Dec. 27)
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...